State-of-the-Art BP-DES: Optimizing Antiplatelet Therapy After PCI in Complex and High Bleeding Risk Patients

 

 


CHAIR
 

Juan Granada, MD

Juan Granada, MD
Cardiovascular Research Foundation
New York, NY


FACULTY

Aloke Finn



Aloke Finn
CVPath Institute
Gaithersburg, MD
 

 Ajay Kirtane




Ajay Kirtane, MD
Columbia/Presbyterian
Hospital
New York, NY
 

 Simon Walsh, MD



Simon Walsh, MD
Royal Victoria Hospital
Belfast, Ireland
 

 Robert Yeh, MD



Robert W. Yeh, MD
Beth Israel Deaconess
Boston, MA
 

AGENDA
 

Short and Optimal DAPT: Lessons from the EVOLVE SHORT-DAPT Late Breaking Science
Ajay Kirtane
    
Fundamentals of Stent Design: The BP-DES Sweet Spot
Aloke Finn


IDEAL LM Late Breaking Trial - BP-DES in Complex Lesion PCI with shortened DAPT
Simon Walsh

    
Complex and High-Bleeding Risk Patients: Why We Still Need DES Innovation​
Robert W. Yeh

 

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions. Please review the SYNERGY DFU for full instructions on DAPT.

Please review the SYNERGY DFU for full instructions on DAPT.

 

This program was supported by: Boston Scientific - ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients